265 related articles for article (PubMed ID: 24589459)
1. Androgen-deprivation therapy-induced aggressive prostate cancer with neuroendocrine differentiation.
Lipianskaya J; Cohen A; Chen CJ; Hsia E; Squires J; Li Z; Zhang Y; Li W; Chen X; Xu H; Huang J
Asian J Androl; 2014; 16(4):541-4. PubMed ID: 24589459
[TBL] [Abstract][Full Text] [Related]
2. Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway.
Chen H; Sun Y; Wu C; Magyar CE; Li X; Cheng L; Yao JL; Shen S; Osunkoya AO; Liang C; Huang J
Endocr Relat Cancer; 2012 Jun; 19(3):321-31. PubMed ID: 22389383
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
Kaur H; Samarska I; Lu J; Faisal F; Maughan BL; Murali S; Asrani K; Alshalalfa M; Antonarakis ES; Epstein JI; Joshu CE; Schaeffer EM; Mosquera JM; Lotan TL
Prostate; 2020 Sep; 80(12):1012-1023. PubMed ID: 32649013
[TBL] [Abstract][Full Text] [Related]
4. PC3 is a cell line characteristic of prostatic small cell carcinoma.
Tai S; Sun Y; Squires JM; Zhang H; Oh WK; Liang CZ; Huang J
Prostate; 2011 Nov; 71(15):1668-79. PubMed ID: 21432867
[TBL] [Abstract][Full Text] [Related]
5. New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma.
Sciarra A; Cardi A; Dattilo C; Mariotti G; Di Monaco F; Di Silverio F
Int J Clin Pract; 2006 Apr; 60(4):462-70. PubMed ID: 16620361
[TBL] [Abstract][Full Text] [Related]
6. Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features.
Alberti C
G Chir; 2010; 31(11-12):568-74. PubMed ID: 21232206
[TBL] [Abstract][Full Text] [Related]
7. [Neuroendocrine differentiation in adenocarcinoma of the prostate during hormonal treatment: a case report].
Matsumoto Y; Mibu H; Kagebayashi Y
Hinyokika Kiyo; 2004 Nov; 50(11):813-5. PubMed ID: 15628545
[TBL] [Abstract][Full Text] [Related]
8. Transformation of prostatic adenocarcinoma to well-differentiated neuroendocrine tumor after hormonal treatment.
Gilani S; Guo CC; Li-Ning EM; Pettaway C; Troncoso P
Hum Pathol; 2017 Jun; 64():186-190. PubMed ID: 28159676
[TBL] [Abstract][Full Text] [Related]
9. Neuroendocrine differentiated small cell carcinoma presenting as recurrent prostate cancer after androgen deprivation therapy.
Miyoshi Y; Uemura H; Kitami K; Satomi Y; Kubota Y; Hosaka M
BJU Int; 2001 Dec; 88(9):982-3. PubMed ID: 11851626
[No Abstract] [Full Text] [Related]
10. [Neuroendocrine differentiation in prostate cancer. An unrecognized and therapy-resistant phenotype].
Bonkhoff H; Fixemer T
Urologe A; 2004 Jul; 43(7):836-42. PubMed ID: 15048555
[TBL] [Abstract][Full Text] [Related]
11. Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer.
Chen WY; Zeng T; Wen YC; Yeh HL; Jiang KC; Chen WH; Zhang Q; Huang J; Liu YN
Cancer Lett; 2019 Jan; 440-441():35-46. PubMed ID: 30312731
[TBL] [Abstract][Full Text] [Related]
12. Oncofetal protein glypican-3 is a biomarker and critical regulator of function for neuroendocrine cells in prostate cancer.
Butler W; Xu L; Zhou Y; Cheng Q; Hauck JS; He Y; Marek R; Hartman Z; Cheng L; Yang Q; Wang ME; Chen M; Zhang H; Armstrong AJ; Huang J
J Pathol; 2023 May; 260(1):43-55. PubMed ID: 36752189
[TBL] [Abstract][Full Text] [Related]
13. [Neuroendocrine differentiation in adenocarcinoma of prostate during combined androgen blockade therapy: a case report].
Kitamoto K; Hayashi T; Tamada S; Ezaki K; Kawashima H; Sugimura K; Nakatani T
Hinyokika Kiyo; 2005 Jan; 51(1):33-5. PubMed ID: 15732339
[TBL] [Abstract][Full Text] [Related]
14. Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancers.
Zhang Y; Zheng D; Zhou T; Song H; Hulsurkar M; Su N; Liu Y; Wang Z; Shao L; Ittmann M; Gleave M; Han H; Xu F; Liao W; Wang H; Li W
Nat Commun; 2018 Oct; 9(1):4080. PubMed ID: 30287808
[TBL] [Abstract][Full Text] [Related]
15. Metastatic conventional prostatic adenocarcinoma with diffuse chromogranin A and androgen receptor positivity.
Roudier MP; True LD; Vessella RL; Higano CS
J Clin Pathol; 2004 Mar; 57(3):321-3. PubMed ID: 14990610
[TBL] [Abstract][Full Text] [Related]
16. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma.
Aprikian AG; Cordon-Cardo C; Fair WR; Reuter VE
Cancer; 1993 Jun; 71(12):3952-65. PubMed ID: 7685237
[TBL] [Abstract][Full Text] [Related]
17. Anti-androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals.
Dang Q; Li L; Xie H; He D; Chen J; Song W; Chang LS; Chang HC; Yeh S; Chang C
Mol Oncol; 2015 Aug; 9(7):1241-51. PubMed ID: 25817444
[TBL] [Abstract][Full Text] [Related]
18. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation.
Epstein JI; Amin MB; Beltran H; Lotan TL; Mosquera JM; Reuter VE; Robinson BD; Troncoso P; Rubin MA
Am J Surg Pathol; 2014 Jun; 38(6):756-67. PubMed ID: 24705311
[TBL] [Abstract][Full Text] [Related]
19. Neuroendocrine differentiation in the 12T-10 transgenic prostate mouse model mimics endocrine differentiation of pancreatic beta cells.
Gupta A; Wang Y; Browne C; Kim S; Case T; Paul M; Wills ML; Matusik RJ
Prostate; 2008 Jan; 68(1):50-60. PubMed ID: 18004726
[TBL] [Abstract][Full Text] [Related]
20. EGFR-upregulated LIFR promotes SUCLG2-dependent castration resistance and neuroendocrine differentiation of prostate cancer.
Lin SR; Wen YC; Yeh HL; Jiang KC; Chen WH; Mokgautsi N; Huang J; Chen WY; Liu YN
Oncogene; 2020 Oct; 39(44):6757-6775. PubMed ID: 32963351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
